Form 4: Bristol-Myers Squibb Director Acquires Deferred Share Units

Michael R. McMullen, a director at Bristol-Myers Squibb, acquired 3,562.341 deferred share units on February 1, 2025, convertible to common stock upon settlement.

Summary

• On February 1, 2025, Michael R. McMullen, a director of Bristol-Myers Squibb, acquired 3,562.341 deferred share units.
• These units are convertible into shares of common stock upon settlement, which occurs when McMullen ceases to be a director or at a previously specified future date.
• The price per share for the deferred share units was $58.95.
• Following the transaction, McMullen beneficially owns 7,826.704 deferred share units, which includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The acquisition of deferred share units by a director is generally viewed as a positive sign, indicating confidence in the company's future. However, it's a routine transaction and doesn't necessarily indicate a major shift in the company's prospects.

Positives

• The acquisition of deferred share units by a director signals confidence in the company's future performance.

Future Outlook

The deferred share units will be converted into common stock upon settlement, which occurs when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

Industry Context

Director share acquisitions are common in publicly traded companies and are often seen as a positive sign, indicating management's belief in the company's future prospects. This transaction is a routine disclosure of such activity.

Comparison to Industry Standards

• Director compensation packages often include deferred share units to align their interests with those of long-term shareholders.
• Companies like Pfizer (PFE) and Johnson & Johnson (JNJ) also utilize similar compensation strategies for their directors.
• The vesting and settlement terms are typical for deferred share unit programs in the pharmaceutical industry.

Stakeholder Impact

• The acquisition of deferred share units by a director can positively influence shareholder sentiment.

Key Dates

Keywords

Deferred Share Units, Director, Bristol-Myers Squibb, BMY, Beneficial Ownership, Form 4, SEC Filing